Curcumin affects the prognosis of renal cell carcinoma (RCC) through a negative feedback loop of H19/miR-675/HDAC/CTCF

Type
Research paper

Keywords
curcumin, renal cell carcinoma, H19, HDAC, miR-675, CTCF

Abstract
Introduction
The objective of this study was to explore the role of Curcumin (CUR) in the control of renal cell carcinoma (RCC) as well as the molecular mechanism underlying the effect of CUR.

Material and methods
Real-time PCR, Western-blot analysis, immunohistochemistry (IHC) assay, and luciferase assay were utilized to detect the effect of CUR.

Results
Mesoscale nanoparticles (particles) could be safely and preferentially accumulated in the kidney in a dose-dependent manner, and the specific localization of particles in the kidney reached its maximum level at a dose of 25 mg/kg. Treatment with CUR alleviated RCC by up-regulating the expression of H19 and miR-675 while down-regulating the expression of HDAC1 and HDAC6 in RCC rats. Furthermore, the underlying mechanism of CUR in the regulation of H19 was explored, and it was revealed that CUR increased H19 expression via increasing the translational efficiency of H19promoter. Therefore, the treatment with CUR increased the levels of H19 and miR-675 mRNAs while reducing the expression of HDAC1 and HDAC6. According to a computational analysis, HDAC1 and HDAC6 were both direct targets downstream of miR-675, and miR-675 mimics could decrease the luciferase activity of cells transfected by wild-type HDAC1 and HDAC6 3’UTR. In addition, miR-675 but not CTCF reduced the protein levels of HDAC1 and HDAC6. Nevertheless, CTCF increased the luciferase activity of cells transfected by H19 promoter, while miR-675 mimics decreased the effect of CTCF.

Conclusions
In this study, we suggested that CUR could affect the prognosis of RCC by establishing a negative feedback loop of H19/miR-675/HDAC/CTCF.
Curcumin affects the prognosis of renal cell carcinoma (RCC) through a negative feedback loop of H19/miR-675/HDAC/CTCF

Fuhe Liu¹, Wenjuan Ni¹, Songlin Yu¹, Fanzhu Li², Jiazhen Zhu², Ziwei Chen¹, Ying Cheng³, Chaoquin Li²

2. College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 311402, PR China.

Corresponding author: Fuhe Liu

Institution: Zhejiang Pharmaceutical College, Ningbo, Zhejiang, 315100, PR China
Address: 888, Eastern Section of Yinxian Avenue, Ningbo, Zhejiang Province, China, 315100
Email: curuculfh@yeah.net

Abstract

Background: The objective of this study was to explore the role of Curcumin (CUR) in the control of renal cell carcinoma (RCC) as well as the molecular mechanism underlying the effect of CUR. Method: Real-time PCR, Western-blot analysis, immunohistochemistry (IHC) assay, and luciferase assay were utilized to detect the effect of CUR. Result: Mesoscale nanoparticles (particles) could be safely and preferentially accumulated in the kidney in a dose-dependent manner, and the specific localization of particles in the kidney reached its maximum level at a dose of 25 mg/kg. Treatment with CUR alleviated RCC by up-regulating the expression of H19 and miR-675 while down-regulating the expression of HDAC1 and HDAC6 in RCC rats. Furthermore, the underlying mechanism of CUR in the regulation of H19 was explored, and it was revealed that CUR increased H19 expression via increasing the translational efficiency of H19 promoter. Therefore, the treatment with CUR increased the levels of H19 and miR-675 while reducing the expression of HDAC1 and HDAC6. According to a computational analysis, HDAC1 and HDAC6 were both direct targets downstream of miR-675, and miR-675 mimics could decrease the luciferase activity of cells transfected by wild-type HDAC1 and HDAC6 3’UTR.
In addition, miR-675 but not CTCF reduced the protein levels of HDAC1 and HDAC6. Nevertheless, CTCF increased the luciferase activity of cells transfected by H19 promoter, while miR-675 mimics decreased the effect of CTCF. **Conclusion:** In this study, we suggested that CUR could affect the prognosis of RCC by establishing a negative feedback loop of H19/miR-675/HDAC/CTCF.

**Running title:** Curcumin affected RCC prognosis via the H19/miR-675/HDAC/CTCF axis

**Keywords:** Curcumin, Renal cell carcinoma, H19, miR-675, HDAC, CTCF

**Introduction**

Renal cell carcinoma (RCC) is the most common type of neoplasm of the kidney, and despite numerous studies the set of predictive and prognostic markers of survival are still unknown [1]. RCC can be divided into three histological subtypes, i.e., clear cell (ccRCC), papillary (pRCC), and chromophobe tumors (chRCC), which account for 85–90% of all RCC cases [1].

Extracted from rhizomes of Curcuma plants [2], curcumin (CUR) have anti-cancer, anti-inflammatory, and anti-oxidant properties [3]. In a recent study, CUR was confirmed as a potent suppressor of tumor angiogenesis, metastasis, proliferation and initiation, in renal, liver, pancreatic, lung, and breast cancers [4]. In addition, as a pigment extracted from rhizoma curcumae longae, CUR plays several biological roles such as anti-oxidative, stomach-protecting, liver-protecting, anti-coagulation, anti-inflammatory, lipid-lowering, anti-tumor, anti-atherosclerotic, anti-rheumatic, and cholagogic roles [5]. It was suggested that HOTAIR is implicated in CUR-induced suppression of RCC metastasis, thus providing a basis for using CUR in the treatment of metastatic RCC [2]. In addition, H19 is upregulated in gastric cancers and promotes cancer cell proliferation by inactivating p53 [6, 7]. Interestingly, CUR was found to downregulate H19 in human gastric cancer cells [8].

Many noncoding RNAs (ncRNAs) can regulate gene expression during pathogenesis and human development. Among these ncRNAs, miRNAs (~22nts) are deemed as key gene regulators through their complementary binding with target mRNAs, while IncRNAs (>200nts) exhibit multiple functions in abnormal and normal tissues [9]. Previous work had reported the
regulatory control of miRNA processing based on RNA-RNA interactions, highlighting the increasing complexity of ncRNA mediated regulatory networks [10]. For example, IncRNA UCA1 has been reported to be involved in the development and progression of many types of tumors including breast cancer, gastric cancer, and bladder cancer [11]. And IncRNA-H19 acts as an oncogene in a wide range of pathological processes during tumor metastasis and growth, such as during clear cell renal cell carcinomas (ccRCC) [12]. It was shown that IncRNA-H19 is negatively regulated by miR-29a-3p in ccRCC [13].

Histone deacetylases (HDACs) are enzymes regulating gene expression and chromatin status. There are type I, type II, type III and type IV HDAC [14]. In particular, type I HDACs are overexpressed in ccRCC [15], while type II HDACs stabilized HIF-1α in prostate and renal tumors [7]. Therefore, class II HDACs can be potentially used in identifying ccRCC patients suitable for treatments by HDAC suppressors [16]. In humans, CCCTC-binding factor (CTCF) was reported to be involved in CTCF-dependent regulation of the imprinted genes Igf2 and H19 [17]. Although unmethylated ICR is crucial for CTCF binding, CTGF binding can neither suppress IGF2 transcription nor enhance H19 expression [18, 19]. In addition to the methylation of ICR, other factors may affect H19 and IGF2 expression.

The administration of CUR could up-regulate the expression of H19 [16]. In addition, HDAC can be targeted by miR-675, which is hosted in H19 [20]. Furthermore, HDAC could activate and work with CTCF jointly to negatively regulate the transcription efficiency of H19 promoter, and to maintain the homeostasis in the cells [20]. In this study, we treated the rats in a RCC rodent model with CUR and investigated the role of relevant signaling pathways implicated in the CUR functions.

Materials and Methods

Animal and treatment

The protocol of this study was approved by our Animal Care and Use Committee. A rat RCC model was established according to the procedure in a published work by Hammers HJ et al. [21]. In brief, 4-8 weeks old male SPF nude mice were obtained from Charles River Laboratories (Wilmington, MA) and breed under pathogen-free conditions. Subsequently, primary xenografts
derived from a cell line (IH23.1) of renal tumor were implanted into the nude rats. When the size of tumor growth in the rats reached 1,000 mm$^3$, the tumors were removed from the rats and dissected into 3 × 3 × 3 mm$^3$ sections, which were transplanted into new groups of untreated rats for amplification and drug treatment. The rats model groups were set up as: RCC group (N=12) in which the control rats were treated with empty particles, RCC-MNP-CUR group (25 mg/kg, N=12) in which the rats were treated with particles carrying 25 mg/kg CUR and RCC-MNP-CUR group (50 mg/kg, N=12) in which the rats were treated with particles carrying 50 mg/kg CUR. The growth of tumors in different groups was evaluated biweekly using a caliper.

**Real-time PCR**

Cells were treated by a miRNeasy kit (Qiagen, Hilden, Germany) to obtain total RNA, which was converted into cDNA using a RT kit (TransGen Biotech, Beijing, China). Then, real-time PCR was carried out using a SuperScript One-Step Kit (Thermo Fisher, Waltham, MA) per kit instruction to measure H19 (F: 5'- TGCTGCACTTTA CAACCCTG-3'; R: 5'- ATGGTGCTTTTGATGTT GGGC-3'), miR-675 (F: 5'- TGTTGCGGAGAGGGC-3'; R: 5'- GAACATGTCTGCGTATCTC-3'), HDAC1 mRNA (F: 5'- GGTCCAAATGCAGGCGATTCCT-3'; R: 5'- GAACATGTCTGCGTATCTC-3'), HDAC6 mRNA (F: 5'- GCCTCAATCAGGAGCATTCC-3'; R: 5'- GGTTGCCTTCTTGGTGACCAACT-3'), and CTCF mRNA (F: 5'- GACCACACAAGTGCCATCTCTG-3'; R: 5'- ATGTGCGAGTCTGGGCAGACTGTG-3') expression.

**Cell culture**

HEK293 and CAKI2 cells were maintained in a DMEM medium (Invitrogen, Carlsbad, CA) and then transfected by 50 nmol/well of miR-675 or 2 μg/well of p-CTCF plasmid using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) per manufacturer’s instruction. Transfected cells were collected 48 h later for subsequent experiments.

**Vector construction and luciferase assay**

A bioinformatic tool at [https://cm.jefferson.edu/rna22/Interactive/](https://cm.jefferson.edu/rna22/Interactive/) was used to locate miR-675 binding sites of HDAC1 and HDAC6. PCR was then applied for the amplification of the 3'UTR region in HDAC1 and HDAC6 genes. The target fragment was then cloned into a pmirGLO (Promega, Madison, WI) vector. The obtained plasmids (pHDAC1-wt and pHDAC6-wt) were
then amplified using bacteria culture, and site-specific mutagenesis was performed on the miR-675 binding site of pHDAC1-wt and pHDAC6-wt to construct pHDAC1-mut and pHDAC6-mut plasmids. Similarly, to investigate the effect of CTCF and miR-675 on the promoter of H19, the promoter of H19 was inserted into the pmirGLO vector to generate a pH19-wt plasmid. In addition, site-specific mutagenesis was performed on the miR-675 binding site of pH19-wt to construct a pH19-mut plasmid. Then, luciferase assays were done by co-transfecting HEK293 and CAKI2 cells with miR-675 and different plasmids. Following 48 h transfection, the luciferase activity in the cells was detected using a luciferase assay kit (Promega, Madison, WI) per kit instruction.

Western blot

Protein was isolated from HEK293 and CAKI2 cells, resolved by 10% SDS-PAGE, and blotted onto PVDF membranes, which were blocked using 5% FBS, incubated with anti-HDAC1, anti-HDAC6 and anti-CTCF primary antibodies overnight at 4°C, rinsed, incubated for 1 h at room temperature with HRP-tagged secondary antibody (Abcam, Cambridge, MA), developed with ECL reagents (Thermo Fisher Scientific, Waltham, MA) and analyzed with an imaging system (Bio-Rad, Hercules, CA) using GAPDH as an internal control to determine the relative protein expression of HDAC1, HDAC6 and CTCF.

Immunohistochemistry

Tissue samples were de-waxed by xylene, treated by gradient ethanol for dehydration, blocked with 5% H2O2 and 10% normal goat serum in sequence, incubated at 4°C overnight with monoclonal anti-HDAC1 and anti-HDAC6 antibodies (Abcam, Cambridge, MA), washed, further incubated with appropriate secondary antibodies at 37°C for 1 h, counter-stained with dianaminobenzidine, mounted, and assessed using microscopy (IX73, Olympus, Tokyo, Japan).

Hematoxylin-eosin (HE) staining

Freshly collected tissue samples were fixed using 10% formalin, embedded, cut into sections of 3 μm in thickness, dewaxed using xylene, treated by gradient ethanol for dehydration, stained
with hematoxylin for 7 min, washed, counter-stained with eosin for 1 min, dried, mounted in neutral balsam, photographed, and assessed for malignancy score.

Statistical analysis

Statistical analysis was done in SPSS 21.0 (IBM, Armonk, NY). All results were expressed using mean ± SD. Statistical differences were compared using student t-test and one-way ANOVA. An α value of 0.05 was chosen to determine statistical significance.

Results

Selectivity of particles in the kidney based on different doses

To determine the optimal dose of MNP treatment in the kidney, 25 mg/kg and 50 mg/kg of fluorescence-labeled particles were injected into the rats and the localization of particles in the kidney was examined at different time points after injection. As shown in Fig. 1A, particles could be specifically accumulated in the kidney but not other organs in a dose-dependent manner. As shown in Fig. 1B, the retention of particles in the kidney was maximized at a dose of 25 mg/kg. As shown in Fig. 1C, the particles remained in the kidney for up to 28 days. As shown in Fig. 1D, E, and F, no obvious changes in serum BUN, serum creatinine and white blood cell count were observed after the injection with particles, indicating that these particles were safe in the kidney.

Effect of CUR on RCC

HE staining was performed to study the effect of CUR on RCC after different dose of CUR (25 mg/kg and 50 mg/kg) were delivered into RCC rats using particles. As shown in Fig. 2, a higher level of malignance was observed in the RCC group as compared with that in the RCC-MNP-CUR (25 mg/kg) and RCC-MNP-CUR (50 mg/kg) groups, while the level of malignance in the RCC-MNP-CUR (25 mg/kg) group showed no significant difference compared with that in the RCC-MNP-CUR (50 mg/kg) group.

Effect of CUR on the expression of H19, miR-675 and HDAC
The effect of CUR on the expression of H19, miR-675 and HDAC was detected using real-time PCR, Western-blot analysis and IHC assay. As shown in Fig. 3, the administration of CUR apparently up-regulated the expression of H19 (Fig. 3A) and miR-675 (Fig. 3B), while the treatment with CUR remarkably down-regulated the mRNA (Fig. 3C and D) and protein (Fig. 3E) levels of HDAC1 (Fig. 3C) and HDAC6 (Fig. 3D). According to the IHC results, the levels of HDAC1 (Fig. 4) and HDAC6 (Fig. 5) proteins in the RCC-MNP-CUR (25 mg/kg) and RCC-MNP-CUR (50 mg/kg) groups were much lower than those in the RCC group.

**CUR increased H19 expression by increasing the translational efficiency of H19 promoter**

Real-time PCR, Western-blot analysis and luciferase assay were carried out to clarify the effect of CUR on the expression of H19, miR-675 and HDAC. As shown in Fig. 6, the luciferase activity in HEK293 cells (Fig. 6A) showed a stepwise increase at the increasing dose of CUR. Meanwhile, the treatment with CUR dose-dependently increased the levels of H19 (Fig. 6B) and miR-675 (Fig. 6C) in HEK293 cells. In contrast, the treatment with CUR dose-dependently decreased the levels of HDAC1 and HDAC6 proteins in HEK293 cells (Fig. 6D). Similar results were observed in CAKI2 cells (Fig. 6E-H).

**MiR-675 directly targeted the 3’UTR of HDAC1 and HDAC6**

Computational analysis was performed to identify HDAC1 (Fig. 7A) and HDAC6 (Fig. 7D) as candidate genes of miR-675. In addition, a complementary binding site of miR-675 was located in the 3’UTRs of HDAC1 or HDAC6. Furthermore, the luciferase activity of HEK293 (Fig. 7B and 7E) and CAKI2 (Fig. 7C and 7F) cells co-transfected with miR-675 mimics and wild-type 3’UTR of HDAC1 or HDAC6 was significantly reduced compared with that in the NC (negative control) cells. All these results collectively suggested that miR-675 directly bond to the 3’UTRs of HDAC1 and HDAC6.

**Effect of CTCF on HDAC expression and translational efficiency of H19 promoter**

HEK293 and HEK293 cells were co-transfected with miR-675 mimics and constructs of CTCF, and then the levels of HDAC1 and HDAC6 as well as the luciferase activity of H19 promoter in transfected cells were measured. As shown in Fig. 8, CTCF showed no effect on the protein


levels of HDAC1 and HDAC6 while miR-675 mimics reduced the protein levels of HDAC1 and HDAC6 in HEK293 cells (Fig. 8A). Furthermore, CTCF up-regulated the luciferase activity of H19 promoter in HEK293 cells (Fig. 8B), while the transfection with miR-675 mimics reduced the luciferase activity of H19 promoter to a certain extent. Similar results were observed in CAKI2 cells (Fig. 8C and D).

Schematic description of the effect of CUR on the negative feedback loop of H19/miR-675/HDAC/CTCF

As shown in Fig. 9, it has been shown that the administration of CUR could down-regulate the expression of H19. In addition, we found that, since miR-675 was located within the chromosome segment of H19, the increase in H19 expression could promote the expression of miR-675. Furthermore, HDAC was found in this study as a target gene of miR-675 in HEK293 and HEK293 cells. Finally, HDAC could reduce the binding affinity of CTCF, which would result in the suppressed transcription efficiency of H19 promoter, thus leading to the formation of negative feedback loop of H19/miR-675/HDAC/CTCF.

Discussion

In this study, we found that particles could be specifically and safely accumulated in the kidney in dose-dependently, and the localization of particles in the kidney reached its maximum level at a dose of 25 mg/kg. Furthermore, we conjugated CUR with particles and used the conjugated particles to treat RCC rats. The results showed that the administration of CUR could attenuate the severity of RCC malignancy.

As a material derived from Curcuma longa, CUR plays extensive therapeutic roles CUR in preventing tumor progression, inhibiting angiogenesis, inducing tumor apoptosis and increasing tumor susceptibility to radiotherapy and chemotherapy [22]. In addition, CUR has been utilized in the treatment of pancreatic and colorectal cancers [23]. Accumulating data suggested that CUR can target c-Myc, p53, nuclear factor-κB, Notch1 and cyclooxygenase-2 [8]. CUR also plays an essential role in enhancing the radiosensitivity of several cancers, such as prostate cancer, hepatocellular carcinoma, and colorectal cancer [24]. It was observed previously that CUR could significantly elevate the radiosensitivity of ACHN tumor cells by damaging the their
 ultrastructures and by effectively suppressing ACHN cell growth [25]. Also, other regulation mechanisms of CUR upon RCC have been reported. For example, Zhang et al. demonstrated that CUR exerts its anti-cancer effect via modulating the PI3K/AKT signaling pathway in the treatment of RCC [26], and Seo et al. further reported that combined treatment with mTOR inhibitor NVP-BEZ235 and CUR could induce apoptosis of human renal carcinoma Caki cells via modulating the level of p53-dependent Bcl-2 mRNA and Mcl-1 protein [27]. Moreover, the study by Xu et al. reported that CUR also enhanced human renal carcinoma cell apoptosis via the up-regulation of YAP/p53 [28]. And Pei et al. demonstrated that the level of HOTAIR not only was closely related with the migration of RCC cells, but also was involved in the CUR-induced inhibition of RCC metastasis [29].

CUR inhibits cancer cell proliferation by indirectly or directly binding to multiple targets such as growth factors and transcription factors [30]. In particular, c-Myc is a key oncogene suppressed by CUR [30]. Furthermore, c-Myc can activate H19 by binding to its promoter and subsequently induce tumor development [31], such as the progression of gastric cancers [32]. It was demonstrated that exogenously administered CUR decreased H19 expression [16]. And H19 mainly exerts its cancer-promoting effect through miR-675, a small noncoding RNA transcribed from H19 [33]. In this research, we measured the effect of CUR on H19, miR-675 and HDAC expression, and found that CUR up-regulated H19 and miR-675 expression while down-regulating HDAC1 and HDAC6 expression. In addition, we investigated whether CUR increased the expression of H19 by increasing the translation of H19 promoter, and showed that CUR indeed increased the luciferase activity of H19 promoter in HEK293 cells.

Histone deacetylases (HDACs) could respond to signals regulating a wide and complicated array of biological processes, such as metabolism and adipocyte differentiation [34]. To date, 18 HDACs have been found in mammalian species [35]. It was shown that miR-675 and H19 could reduce the level of HDAC 4 and 5 [36]. Furthermore, miR-675 binds to the 3’ UTRs of HDAC 4 – 6 to reduce their expression, while HDACs 1, 2, and 3 undergo minimal changes in the presence of miR-675 [20]. Epigenetic changes were shown as the result of induction by abnormal levels of HDACs and subsequent tumor progression and development.
Immunohistologic evaluation of 44 RCC patients has shown reduced histone acetylation [37]. Therefore, it was hypothesized that the increase in acetylated histone can benefit RCC treatment. Indeed, HDAC-inhibitors were shown to block the invasion and growth of RCC [38].

H19 was shown as regulated by epigenetic mechanisms and chromatin structures, such as CTCF insulator and DNA methylation [17]. HDACs obtained from cell extracts could bind to the zinc-finger domain of CTCF [39], while the suppression of HDAC could reduce H19 expression by blocking CTCF occupancy on the imprinting control region (ICR) of H19 [20]. Furthermore, H19 was shown as controlled by epigenetic mechanisms and chromatin structures, such as, CTCF insulator and DNA methylation [17]. Therefore, a proper ICR was necessary to achieve a stable binding between CTCF and H19 promoter [17]. Here, we confirmed HDAC1 and HDAC6 as miR-675 targets. In fact, miR-675 mimics in HEK cells reduced the luciferase activity of wild-type 3’UTRs of HDAC1 and HDAC6. Moreover, we found that CTCF exerted no effect on HDAC1 and HDAC6 expression but increased the luciferase activity of H19 promoter.

However, there were limitations of this study. The conclusion made in our study needs further validation in clinical trial to test the effect of CUR on the prognosis of RCC. Also, it is possible that CUR could effect upon RCC via different signaling pathways, which requires more comprehensive investigations in our future study.

**Conclusion**

In summary, we suggested that CUR could affect the prognosis of RCC by establishing a negative feedback loop of H19/miR-675/HDAC/CTCF, while the presence of CUR down-regulated H19 expression. In addition, we found that, since miR-675 was located within the chromosome segment of H19, the increase in H19 expression could promote the expression of miR-675. Furthermore, HDAC was reported as a miR-675 target in human cells and played a very important role in RCC. Finally, HDAC could reduce the binding affinity of CTCF upon H19 promoter, which inhibited the transcription efficiency of H19 promoter, establishing a negative feedback loop of H19/miR-675/HDAC/CTCF.

**Acknowledgement**
This Project supported by Scientific Research Fund of Zhejiang Provincial Education Department (No. Y201840551), Traditional Chinese Medicine Science and Technology Plan of Zhejiang Province (No.2018ZQ012, No.2018ZQ013), Opening Project of Zhejiang Provincial First-rate Subject (Chinese Traditional Medicine), Zhejiang Chinese Medical University (No. Ya2017007)

Conflict of interest

None

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Figure legends

Figure 1

Selectivity of particles in the kidney based on different doses (* P value < 0.05, vs. 25 mg/kg)

A: particles could be specifically accumulated in the kidney in a dose-dependent manner.

B: Specific localization of particles in the kidney was maximized at a dose of 25 mg/kg.

C: particles could remain in the kidneys for up to 28 days.

D: There was no obvious difference in serum BUN after the injection with particles.

E: There was no obvious difference in serum creatinine after the injection with particles.

F: There was no obvious difference in white blood cell counts after the injection with particles.

Figure 2

The treatment with CUR in RCC rats reduced the severity of RCC malignancy.

Figure 3

Real-time PCR and Western-blot analysis were performed to determine the effect of CUR on the expression of H19, miR-675 and HDAC (* P value < 0.05, vs. RCC rats)
A: Administration of CUR (25 mg/kg or 50 mg/kg) increased the expression of H19 mRNA in RCC rats.

B: Administration of CUR (25 mg/kg or 50 mg/kg) increased the expression of miR-675 mRNA in RCC rats.

C: Treatment with CUR (25 mg/kg or 50 mg/kg) decreased the expression of HDAC1 mRNA in RCC rats.

D: Treatment with CUR (25 mg/kg or 50 mg/kg) decreased the expression of HDAC6 mRNA in RCC rats.

E: CUR (25 mg/kg or 50 mg/kg) decreased the protein levels of HDAC1 and HDAC6 in RCC rats.

**Figure 4**

IHC assay was carried out to evaluate the effect of CUR on the protein expression of HDAC1. It was found that the RCC-MNP-CUR (25 mg/kg) and RCC-MNP-CUR (50 mg/kg) groups showed a lower protein level of HDAC1 compared with that in the RCC group.

**Figure 5**

IHC assay was carried out to evaluate the effect of CUR on the protein expression of HDAC6, and it was found that the RCC-MNP-CUR (25 mg/kg) and RCC-MNP-CUR (50 mg/kg) groups displayed a lower protein level of HDAC6 compared with that in the RCC group.

**Figure 6**

CUR increased H19 expression by increasing the translational efficiency of H19 promoter (* P value < 0.5, vs. NC group)

A: Luciferase activity of H19 promoter was dose-dependently increased after treating HEK293 cells with CUR.

B: Luciferase activity of H19 promoter was dose-dependently increased after treating CAKI2 cells with CUR.

C: CUR up-regulated H19 expression in a dose-dependent manner in HEK293 cells.
D: CUR up-regulated H19 expression in a dose-dependent manner in CAKI2 cells.

E: The level of miR-675 was dose-dependently increased in HEK293 cells treated with CUR.

F: The level of miR-675 was dose-dependently increased in CAKI2 cells treated with CUR.

G: CUR dose-dependently down-regulated the protein expression of HDAC1 and HDAC6 in HEK293 cells.

H: CUR dose-dependently down-regulated the protein expression of HDAC1 and HDAC6 in CAKI2 cells.

**Figure 7**

MiR-675 directly targeted the 3’UTRs of HDAC1 and HDAC6 (* P value < 0.5, vs. mimic NC group)

A: The 3’UTR of HDAC1 was targeted by miR-675 with potential “hits” in the 3’UTR of HDAC1.

B: Luciferase activity of wild-type HDAC1 3’UTR was reduced in HEK293 cells over-expressing miR-675.

C: Luciferase activity of wild-type HDAC1 3’UTR was reduced in CAKI2 cells over-expressing miR-675.

D: Schematic comparison of the “seed sequences” in miR-675 and the 3’ UTR of HDAC6.

E: Luciferase activity of HEK293 cells co-transfected with miR-675 mimics and wild-type 3’UTR of HDAC6 showed reduced luciferase activity.

F: Luciferase activity of CAKI2 cells co-transfected with miR-675 mimics and wild-type 3’UTR of HDAC6 showed reduced luciferase activity.

**Figure 8**

Effect of CTCF on HDAC expression and the translational efficiency of H19 promoter (* P value < 0.5, vs. NC group; # P value < 0.5, vs. pc-CTCF group)

A: CTCF showed no effect on the protein levels of HDAC1 and HDAC6 in HEK293 cells, while miR-675 reduced the protein levels of HDAC1 and HDAC6 in these cells.
B: CTCF showed no effect on the protein levels of HDAC1 and HDAC6 in CAKI2 cells, while miR-675 reduced the protein levels of HDAC1 and HDAC6 in these cells.

C: CTCF increased the luciferase activity of H19 promoter in HEK293 cells, while miR-675 mimics reduced the luciferase activity of H19 promoter to a certain extent.

D: CTCF increased the luciferase activity of H19 promoter in CAKI2 cells, while miR-675 mimics reduced the luciferase activity of H19 promoter to a certain extent.

Figure 9

Schematic description of the effect of CUR on the negative feedback loop of H19/miR-675/HDAC/CTCF

References


24 Goel A, Aggarwal BB: Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 2010;62:919-930.


Fig 1-revised
Fig 2

RCC | RCC + MNPs -CUR 25 mg/kg | RCC + MNPs -CUR 50 mg/kg
Fig 3-revised
Fig 5
Fig 6-revised

(A) Relative luciferase activity

(B) Relative expression of HIF1α

(C) Relative expression of miR-675

(D) Western blot analysis of HDAC1, HDAC6, and β-actin

(E) Relative luciferase activity

(F) Relative expression of HIF1α

(G) Relative expression of miR-675

(H) Western blot analysis of HDAC1, HDAC6, and β-actin
Fig 7-revised
Fig 8-revised
Curcumin $\rightarrow$ H19 $\uparrow$ $(+)$ miR-675 $\uparrow$ $(−)$ HDAC1 HDAC6 $\downarrow$ Apoptosis $\uparrow$

$(−)$

Reduce the binding affinity of CTCF with the promoter of H19

Fig 9